A European group has examined the risk of progression to Alzheimer’s disease for the four MCI subgroups outlined in the National Institute on Aging-Alzheimer’s Association (NIA-AA) recommendations (Guo et al. Eur Arch Psychiatry Clin Neurosci 2012; epublished August 30, 2012).
Latest News
GDS recommended for depression screening in PD
November 21, 2012The Methods of Optimal Depression Detection in Parkinson’s Disease (MOOD-PD) study has reviewed patient self-report scales, concluding that the 30-item Geriatric Depression Scale (GDS) is the most efficient tool to screen for clinical depression in PD patients (Williams et al. Neurology 2012;78:998-1006).
FDA delays review of alemtuzumab
November 7, 2012The U.S. Food and Drug Administration has issued a Refuse to File (RTF) letter in response to Genzyme’s application for approval of alemtuzumab (Lemtrada) as a treatment for MS. The RTF letter requires that Genzyme reorganize the data presented and resubmit its application. Although no new data are required, the RTF is expected to delay any approval of the drug in MS by at least six months. The drug is currently under review by the European Medicines Agency.
Combination therapy superior to monotherapy for psychotic depression
November 7, 2012A meta-analysis of 8 treatment trials (n=762) has concluded that a combination of an antidepressant with an antipsychotic agent is better than either alone in the treatment of psychotic depression (Farahani & Correll. J Clin Psychiatry 2012;73:486-496).